FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

12 letters match. Newest first.

  1. InvaDerm, Inc.

    FDA says InvaDerm, Inc. of Somerset, NJ, markets unapproved new drugs without FDA-approved applications.

    High risk
  2. NSE Products, Inc. DBA Nu Skin Enterprises, Inc.

    FDA warns NSE Products (Nu Skin) over incomplete drug listing data for AP-24 products and 61 inactivated listings.

    Low
  3. Shenzhen Hengkaifeng Commerce and Trade Co., Ltd

    Shenzhen Hengkaifeng's Sensitivity Toothpastes listing was inaccurate, making the drug misbranded, FDA says.

    Low
  4. Prodose, Inc. formerly known as Spirit Pharmaceuticals LLC

    Prodose, formerly Spirit Pharmaceuticals, left a cold and flu drug mislisted; FDA calls it misbranded.

    Low
  5. BPI Labs, LLC

    BPI Labs distributes unapproved Epinephrine Chloride Nasal Solution in a vial FDA says can be mistaken for injectable epinephrine.

    High risk
  6. Quality CDMO, Inc.

    FDA warned Quality CDMO that its prescription skin and scalp drugs are unapproved and lack FDA-approved applications.

    High risk
  7. Media Networks Sydney Pty Limited

    Media Networks Sydney failed to properly list Mylanta 2go Antacid and Microlax Enema with FDA, making them misbranded.

    Low
  8. Zen Enterprises LLC

    Zen Enterprises failed to correct drug listing files that named a manufacturer not involved in making its balms and hand sanitizers.

    Low
  9. Ehy Holdings, LLC

    FDA warned Ehy Holdings over unupdated drug listings for nicotine patches and creams, calling products misbranded.

    Low
  10. Walgreen Company

    FDA warns Walgreen Company that its Walgreens Sensitive Extra Whitening drug listing is incomplete and inaccurate.

    Low
  11. Lydia Co. Ltd.

    Lydia Co. Ltd. submitted mismatched drug listing data for eight products, leading FDA to remove them from its NDC Directory.

    Low
  12. ECI Pharmaceuticals, LLC

    FDA warned ECI Pharmaceuticals for listing the wrong active ingredient for its estrogen and testosterone drugs, which got them removed from the NDC Directory.

    Low